08:36 AM EDT, 09/24/2025 (MT Newswires) -- Guardant Health's ( GH ) Shield colorectal cancer screening test will be made available to physicians and patients served by Quest Diagnostics ( DGX ) in the US, the companies said Wednesday.
Under the companies' multiyear collaboration, Quest's physician clients will be able to directly order Shield starting Q1 of 2026, according to a joint statement.
Shares of Guardant and Quest were each up more than 2% in recent premarket activity Wednesday.